CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Aug

Today In Oncology

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations

Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer

Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume

Smoking Cessation in Cancer Care: Challenges and Opportunities

GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs: Survival in Older Patients With Cancer and Diabetes